A cell based high-throughput screening approach for the discovery of new inhibitors of respiratory syncytial virus

Virology Journal

Volumn 10, Issue , 2013, Pages

  Chung, Dong Hoon ^a,b   Moore, Blake P ^c,e   Matharu, Daljit S ^d   Golden, Jennifer E ^d   Maddox, Clinton ^c   Rasmussen, Lynn ^c   Sosa, Melinda I ^c   Ananthan, Subramaniam ^c   White, E Lucile ^c   Jia, Fuli ^c,f   Jonsson, Colleen B ^a,b   Severson, William E ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b University of Louisville School of Medicine   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF KANSAS   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Anti infective drugs; Aryl sulfonylpyrrolidines; Automation robotics; Cell based assays; HTS; Human respiratory syncytial virus (hRSV); Sulfonamides

Indexed keywords

ANTIVIRUS AGENT; RIBAVIRIN;

ANTIVIRAL ACTIVITY; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DOSE RESPONSE; DRUG POTENCY; DRUG SCREENING; FLUORESCENCE ACTIVATED CELL SORTING; HIGH THROUGHPUT SCREENING; MOLECULAR LIBRARY; NONHUMAN; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SIGNAL NOISE RATIO; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION; VIRUS STRAIN;

HUMAN RESPIRATORY SYNCYTIAL VIRUS; RESPIRATORY SYNCYTIAL VIRUS;

EID: 84872114706     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-10-19     Document Type: Article

References (49)

1. Respiratory syncytial virus infection: clinical features, management, and prophylaxis. Greenough A, Curr Opin Pulm Med 2002 8 3 214 217 10.1097/00063198-200205000-00011 11981311 (Pubitemid 34409003)
2. Developing new antiviral agents for influenza treatment: what does the future hold? Hayden F, Clin Infect Dis 2009 48 Suppl 1 3 S13 19067613
3. Prevention and treatment of respiratory syncytial virus and parainfluenza viruses in immunocompromised patients. Englund JA, Piedra PA, Whimbey E, Am J Med 1997 102 3A 61 70 discussion 75-6 10868145
4. Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Paramore LC, et al. PharmacoEconomics 2004 22 5 275 284 10.2165/00019053-200422050-00001 15061677 (Pubitemid 38553698)
5. Interactions between respiratory syncytial virus and the host cell: opportunities for antivirus strategies? Sugrue RJ, Expert Rev Mol Med 2006 8 21 1 17 17178008 (Pubitemid 44336391)
6. Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene. Techaarpornkul S, Barretto N, Peeples ME, J Virol 2001 75 15 6825 6834 10.1128/JVI.75.15.6825-6834.2001 11435561 (Pubitemid 32641568)
7. Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. Teng MN, Whitehead SS, Collins PL, Virology 2001 289 2 283 296 10.1006/viro.2001.1138 11689051 (Pubitemid 33141008)
8. Direct visualization of the small hydrophobic protein of human respiratory syncytial virus reveals the structural basis for membrane permeability. Carter SD, et al. FEBS Lett 2010 584 13 2786 2790 10.1016/j.febslet.2010.05.006 20471980
9. The small hydrophobic protein of the human respiratory syncytial virus forms pentameric ion channels. Gan SW, et al. J Biol Chem 2012 287 29 24671 24689 10.1074/jbc.M111.332791 22621926
10. Transcription elongation factor of respiratory syncytial virus, a nonsegmented negative-strand RNA virus. Collins PL, et al. Proc Natl Acad Sci U S A 1996 93 1 81 85 10.1073/pnas.93.1.81 8552680 (Pubitemid 26038106)
11. Role of the M2-1 transcription antitermination protein of respiratory syncytial virus in sequential transcription. Fearns R, Collins PL, J Virol 1999 73 7 5852 5864 10364337 (Pubitemid 29274872)
12. The product of the respiratory syncytial virus M2 gene ORF1 enhances readthrough of intergenic junctions during viral transcription. Hardy RW, Wertz GW, J Virol 1998 72 1 520 526 9420254 (Pubitemid 28048867)
13. Functional cDNA clones of the human respiratory syncytial (RS) virus N, P, and L proteins support replication of RS virus genomic RNA analogs and define minimal trans-acting requirements for RNA replication. Yu Q, Hardy RW, Wertz GW, J Virol 1995 69 4 2412 2419 7884888
14. The NS1 protein of human respiratory syncytial virus is a potent inhibitor of minigenome transcription and RNA replication. Atreya PL, Peeples ME, Collins PL, J Virol 1998 72 2 1452 1461 9445048 (Pubitemid 28116933)
15. The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. Bermingham A, Collins PL, Proc Natl Acad Sci U S A 1999 96 20 11259 11264 10.1073/pnas.96.20.11259 10500164 (Pubitemid 29487368)
16. Vaccine against respiratory syncytial virus. Jeffcoate TN, Lancet 1969 7615 2 311
17. Respiratory syncytial virus: a brief history, in Contemporary diagnosis and management of respiratory syncytial virus. Handbooks in Health Care Co. Hemming VG, Newtown: PA, Weisman LE, Groothuis JR, 2000 7 23
18. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. a randomized double-blind study. Hall CB, et al. N Engl J Med 1983 308 24 1443 1447 10.1056/NEJM198306163082403 6343860 (Pubitemid 13103444)
19. Aerosolized ribavirin in the treatment of patients with respiratory syncytial virus disease. Rodriguez WJ, et al. Pediatr Infect Dis J 1987 6 2 159 163 10.1097/00006454-198702000-00004 3550679 (Pubitemid 17116135)
20. Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants. Paediatr Child Health 1999 4 7 474 489 20212962
21. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. Leyssen P, et al. J Virol 2005 79 3 1943 1947 10.1128/JVI.79.3.1943-1947.2005 15650220 (Pubitemid 40459141)
22. Molecular analysis of the inhibitory effect of phosphorylated ribavirin on the vesicular stomatitis virus in vitro polymerase reaction. Fernandez-Larsson R, et al. Antimicrob Agents Chemother 1989 33 10 1668 1673 10.1128/AAC.33.10.1668 2556073 (Pubitemid 19239154)
23. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Eriksson B, et al. Antimicrob Agents Chemother 1977 11 6 946 951 10.1128/AAC.11.6.946 879760 (Pubitemid 8129651)
24. 1,4-Benzodiazepines as inhibitors of respiratory syncytial virus. Carter MC, et al. J Med Chem 2006 49 7 2311 2319 10.1021/jm051185t 16570927
25. Ribonuclease L, a 2-5A-dependent enzyme: purification to homogeneity and assays for 2-5A binding and catalytic activity. Player MR, et al. Methods 1998 15 3 243 253 10.1006/meth.1998.0628 9735309 (Pubitemid 28457106)
26. A novel, spectrophotometric microneutralization assay for respiratory syncytial virus. Rubino KL, Nicholas JA, J Virol Methods 1992 39 1-2 55 67 1430065
27. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Markland W, et al. Antimicrob Agents Chemother 2000 44 4 859 866 10.1128/AAC.44.4.859-866.2000 10722482 (Pubitemid 30165261)
28. Synthesis and antiviral evaluation of N-carboxamidine-substituted analogues of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine hydrochloride. Gabrielsen B, et al. J Med Chem 1992 35 17 3231 3238 10.1021/jm00095a020 1507208
29. Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus. Andries K, et al. Antiviral Res 2003 60 3 209 219 10.1016/j.antiviral.2003.07.004 14638397 (Pubitemid 37456869)
30. Orally active fusion inhibitor of respiratory syncytial virus. Cianci C, et al. Antimicrob Agents Chemother 2004 48 2 413 422 10.1128/AAC.48.2.413-422. 2004 14742189 (Pubitemid 38141696)
31. Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein. Douglas JL, et al. J Virol 2003 77 9 5054 5064 10.1128/JVI.77.9.5054-5064.2003 12692208 (Pubitemid 36460920)
32. RFI-641 inhibits entry of respiratory syncytial virus via interactions with fusion protein. Razinkov V, et al. Chem Biol 2001 8 7 645 659 10.1016/S1074-5521(01)00042-4 11451666 (Pubitemid 32632532)
33. YM-53403, a unique anti-respiratory syncytial virus agent with a novel mechanism of action. Sudo K, et al. Antiviral Res 2005 65 2 125 131 10.1016/j.antiviral.2004.12.002 15708639 (Pubitemid 40222289)
34. Inhibitors of respiratory syncytial virus replication target cotranscriptional mRNA guanylylation by viral RNA-dependent RNA polymerase. Liuzzi M, et al. J Virol 2005 79 20 13105 13115 10.1128/JVI.79.20.13105-13115. 2005 16189012 (Pubitemid 41433229)
35. In search of a small-molecule inhibitor for respiratory syncytial virus. Douglas JL, Expert Rev Anti Infect Ther 2004 2 4 625 639 10.1586/14787210.2.4. 625 15482225 (Pubitemid 39162370)
36. Isolation and characterization of NMSO3-resistant mutants of respiratory syncytial virus. Kimura K, et al. Antiviral Res 2004 61 3 165 171 10.1016/j.antiviral.2003.09.008 15168797 (Pubitemid 38183056)
37. Informa UK Ltd. Pharmaprojects Pharmaceutical Research & Development Pipeline Intelligence 2008
38. Identification of broad-spectrum antiviral compounds and assessment of the druggability of their target for efficacy against respiratory syncytial virus (RSV). Bonavia A, et al. Proc Natl Acad Sci U S A 2011 108 17 6739 6744 10.1073/pnas.1017142108 21502533
39. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. Zhang JH, Chung TD, Oldenburg KR, J Biomol Screen 1999 4 2 67 73 10.1177/108705719900400206 10838414 (Pubitemid 29278954)
40. In vitro and in vivo influenza virus-inhibitory effects of viramidine. Sidwell RW, et al. Antiviral Res 2005 68 1 10 17 10.1016/j.antiviral.2005.06.003 16087250 (Pubitemid 41338577)
41. Short duration aerosols of JNJ 2408068 (R170591) administered prophylactically or therapeutically protect cotton rats from experimental respiratory syncytial virus infection. Wyde PR, et al. Antiviral Res 2003 60 3 221 231 10.1016/j.antiviral.2003.07.002 14638398 (Pubitemid 37456870)
42. A High-Throughput Screening Strategy to Overcome Virus Instability. Rasmussen L, et al. Assay Drug Dev Technol 2011 9 2 184 190 10.1089/adt.2010. 0298 21050067
43. A simple method of estimating fifty percent endpoints. Reed LJ, Muench H, Am J Hygiene 1938 27 493 497
44. (S)-N-(2,5-Dimethylphenyl)-1-(quinoline-8-ylsulfonyl)pyrrolidine-2- carboxamide as a Small Molecule Inhibitor Probe for the Study of Respiratory Syncytial Virus Infection. Moore BP, et al. J Med Chem 2012 55 20 8582 8587 10.1021/jm300612z 23043370
45. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants. DeVincenzo JP, et al. J Infect Dis 2004 190 5 975 978 10.1086/423213 15295704 (Pubitemid 39120976)
46. Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats. Zhao X, Chen FP, Sullender WM, Virology 2004 318 2 608 612 10.1016/j.virol.2003.10.018 14972528 (Pubitemid 38224303)
47. In vivo selection of respiratory syncytial viruses resistant to palivizumab. Zhao X, Sullender WM, J Virol 2005 79 7 3962 3968 10.1128/JVI.79.7.3962-3968.2005 15767398 (Pubitemid 40388336)
48. Palivizumab-resistant human respiratory syncytial virus infection in infancy. Adams O, et al. Clin Infect Dis 2010 51 2 185 188 10.1086/653534 20528472
49. Stabilization of respiratory syncytial virus (RSV) against thermal inactivation and freeze-thaw cycles for development and control of RSV vaccines and immune globulin. Gupta CK, et al. Vaccine 1996 14 15 1417 1420 10.1016/S0264-410X(96)00096-5 8994316 (Pubitemid 27008256)